Traditional plastic forks shed harmful microplastics. Plastic created from sugar is an alternative

By Jennifer Mcdermott, The Associated Press,

WOBURN, Mass. (AP) — At a Massachusetts lab, pebble-sized pellets are transformed into forks and films that won’t leave persistent microplastics in the environment.

These are bioplastic pellets. CJ Biomaterials ferments sugar to make plant-based polymers that microbes will consume. These alternatives to traditional plastics made of fossil fuels are seen by some as one of many solutions needed to confront global plastic pollution.

At the company’s Woburn research facility, lab technicians recently poured pellets into a molding machine to make forks. The test forks were thin enough for home composting, though too bendy for stabbing a steak. Other batches have been rigid, similar to a typical plastic fork. The technicians melted pellets to roll out flexible films for food packaging, like a bag for baby carrots. The film was quite strong but not stretchy like cling wrap.

They are figuring out how their biopolymers can make products with attributes similar to conventional plastics, but that can go in a composting bin instead of a trash can. Forks and films are breaking down in the lab’s compost bin. Straws that were added are long gone. A recently tossed-in knife showed pitting on the surface as bacteria colonized it, starting to consume the material.

Plastics have never really fundamentally been disrupted. Now, interest in bioplastic is growing because of concern over microplastics. It’s the new “wild card” in this market, said the company’s marketing director Leah Ford.

“I’ve been doing this for a long time and the compostability has always been a really strong driver. But with the greater understanding of microplastics, I think, that’s going to change how people think about materials,” she said.

Traditional plastics last for decades or even centuries as they fragment into harmful microplastics and even smaller nanoplastics. Microplastics have been found in the ocean and the air, in our food and water, and in a wide range of body tissues. The Trump administration, while rolling back many environmental regulations, says it will address contamination from microplastics.

The most common use for bioplastics is packaging

Bioplastics are biobased, meaning they are made completely or partially from a renewable resource, commonly corn or sugar cane; or they are biodegradable, meaning that they break down completely via a natural process. They can also be both, like the polymers made by CJ Biomaterials. It’s a leader in manufacturing polyhydroxyalkanoates, or PHAs, as a polymer that is marine and soil biodegradable.

CJ Biomaterials is trying to replace conventional plastics that are single use or can’t be recycled when contaminated with food scraps. Food waste decomposing in landfills emits methane, a potent greenhouse gas that warms the planet. A container made of pellets from CJ Biomaterials with food scraps could be sent to a composter, unlike a traditional plastic container.

The Woburn lab’s shelves display the company’s successes: compostable cutlery; straws; coated cups for hot beverages and frozen food pouches used in the United States; sushi trays; ramen containers; and reusable paper towels. Lab employees dine with compostable cutlery, drink from compostable cups and make coffee with compostable pods. These products last on shelves because they are not exposed to microorganisms in water or soil.

CJ Biomaterials feeds sugar to microbes that convert it to PHA for energy. The company collects the PHA and turns it into granules. Pellets of this are then sold to other companies that can melt them down and mold them into products. These same bacteria will consume PHA in a compost pile, breaking it down within six months, Ford said.

CJ Biomaterials is part of the $32 billion South Korean conglomerate CJ Group. It has been producing PHA at a manufacturing facility in Pasuruan, Indonesia, since 2022.

One solution with potential to help address the plastic pollution crisis

World Wildlife Fund sees biobased plastics as part of a suite of solutions that are needed. They can reduce the world’s dependency on fossil fuels that cause climate change, said Erin Simon, a WWF vice president. She said the world needs to reduce the amount of plastic being produced, then make the rest sustainably.

Nations are trying to confront the spiraling plastic pollution crisis by crafting a landmark treaty. They have yet to agree on any effective methods to stop plastic pollution, though negotiators plan to meet again early next year.

U.S. Sen. Jeff Merkley has held congressional hearings on plastic pollution, including one exploring alternatives for single-use plastics. He also views bioplastics as one option with potential, among many that are needed. But, he said, more information is needed about how they break down and impact ecosystems and health.

Environmental groups, including the Global Alliance for Incinerator Alternatives, argue that bioplastics maintain the single-use paradigm and distract from real solutions. Some say farmland shouldn’t be used to grow crops for plastic instead of food.

Bioplastics are a small, but growing, share of the market

Globally, biobased plastics represent roughly 0.5% of the more than 400 million metric tons (440 million tons) of plastics produced annually, according to the industry group European Bioplastics. Production is projected to double by 2030 due to rising demand and the emergence of more advanced applications and products, it said.

China, Sweden and the United States are major exporters of natural polymers.

Large sports stadiums and major restaurant chains such as McDonald’s are experimenting with biobased packaging and utensils. The Tous les Jours bakery, part of the CJ Group, uses PHA straws.

There are obstacles to widespread adoption. Bioplastics typically cost more than conventional plastics. Major cities have municipal composting programs, but they are limited elsewhere. A growing number of composting facilities accept compostable bioplastic products, though some refuse out of concern about degraded soil quality. And because bioplastics and conventional plastics often look and feel identical, they can be mixed up and cause problems for composters.

Thirty minutes from the Woburn research lab, Black Earth Compost accepts certified compostable materials. On Monday, compostable cups, cutlery and bin liners were mixed in with a delivery of food scraps and lobster shells. Accepting bioplastics increases the amount of food scraps they receive because people can put an entire compostable container into an organics bin, instead of scraping food out.

Research organization tests biomaterials

The 5 Gyres Institute tested 22 items made of traditional plastic, biobased and biodegradable materials and other alternatives, such as paper and bamboo. Straws, utensils, thin film and bottles were put in different environments across Florida, California and Maine. By the end of the 64-week study, many of the biodegradable materials were gone, or were pitted and cracked as they fragmented. Traditional fossil fuel-based plastics persisted.

Marcus Eriksen, the institute’s co-founder and a researcher, said the synthetic plastic spoon was almost the same as when he first put it in the ocean, but little was left of the spoons made from biodegradable materials.

The California-based nonprofit released the results in 2023. It’s currently repeating the study to evaluate end-of-life scenarios for the new generation of packaging.

Eriksen thinks people should use biodegradable options, especially for packaging. Otherwise, he said, “we’re going to flood the entire biosphere with micro- and nanoplastics.”

___

The Associated Press’ climate and environmental coverage receives financial support from multiple private foundations. AP is solely responsible for all content. Find AP’s standards for working with philanthropies, a list of supporters and funded coverage areas at AP.org.

Jennifer Mcdermott, The Associated Press

Keep it Factual
Add CityNews Toronto as a trusted source on Google to see more local stories from us.

Top Stories

Weight-loss drugs shaping up to be a boon for grocers' pharmacy units

While discount stores have been a bright spot recently for major grocery chains, other units within their empires have been quietly seeing a sales boom: their pharmacies. And it's largely coming from rising sales of weight-loss drugs. The popularity of Ozempic and other GLP-1 drugs, traditionally used to manage Type 2 diabetes, has exploded in recent years thanks to their weight-loss side effects. And as cheaper, generic versions become more widely available, uptake is only expected to rise further. Semaglutides, or GLP-1s as they're sometimes called, are the active ingredient in drugs like Ozempic. For grocers that have pharmacy units, signs of that growth are already noticeable in their financial reports. Loblaw Cos. Ltd., which owns Shoppers Drug Mart and Pharmaprix, reported a roughly 40 per cent surge in GLP-1 sales in each of its last two quarters. "We are beginning to see the impact of GLP-1 drugs going generic. It's still very early, but the initial indications are encouraging," Per Bank, chief executive of Loblaw, told analysts on an earnings call in July. Loblaw executives are projecting double-digit growth for GLP-1 sales in 2027. Metro Inc.'s outgoing chief executive, Eric La Flèche, struck a similar note during its earnings call last month. Metro owns Jean Coutu pharmacies. "Demand fundamentals remain strong with early evidence of increased patient adoption and higher prescription volumes," he said. Loblaw reported its drug retail same-store sales grew 4.6 per cent in its latest quarter, while Metro's pharmacy same-store sales were up 4.8 per cent. Both outpaced same-store sales metrics for food. The gains were driven by the prescriptions category. Even though generic versions of the drug mean lower prices, the growth in volume is still a net positive. "As generic supply continues to build, we expect ongoing expansion of the GLP-1 category to drive low-teens volume and contribution growth," La Flèche told analysts. That's "indicating that higher volumes should more than offset a meaningful portion of the price pressure from generalization," Veritas analyst Kathleen Wong said in a note about Metro's quarterly results in August. "The resulting price deflation is therefore likely to pressure pharmacy same-store sales measured in dollars, but Metro’s early experience suggests that increased accessibility and prescription volumes can offset part of that pressure at the contribution level." Health Canada has so far approved three generic semaglutide products, and is continuing to review more — making the country the first among G7 nations to do so. These used to be called the drug of the rich, said Amar Singh, senior director and head of Canadian retail insights at Kantar. "This drug was expensive, and now, with the generics coming out, this is increasing penetration as the cost has come down and more people can afford it," he said in an interview. Half of the respondents in a Leger poll from March said insurance coverage or a lower-cost generic would increase their likelihood of using a GLP-1. More than half cited weight loss as their primary reason for taking the drug. At that time, eight per cent — or three million Canadians — were on prescription GLP-1s, the survey suggested. With generics increasingly available in the market, Singh said he expects uptake to rise to about 20 per cent over the next year or two. That surge comes as Loblaw and Metro are expanding their pharmacy networks. Loblaw expects to have opened about 200 stores over the last three years, and roughly half are pharmacies, Wong said. Meanwhile, Empire acquired nine Morelli’s pharmacies in Ontario last month that are already situated within some Longo’s grocery stores. Jo-Ann McArthur, president of Nourish Food Marketing, said the increasing popularity of weight-loss drugs could be an opportunity for grocers to tailor customer experiences, especially as attitudes toward food change among weight-loss drug users. For instance, she said grocers could suggest GLP-1-friendly foods and offer meal planning through their loyalty apps, offer health-care insights for those on and off drugs, streamline store shelf labelling and market items that are weight-loss drug friendly. Late last year, Loblaw launched an online weight-management program for people to connect with health care practitioners and see if they qualify for the drugs. "Where they make more money (is) by providing more services and more advice and just making it easier for the consumer to just stay loyal," she said. And it's not just about keeping GLP-1 users within the same ecosystem. "People who are on these drugs often are controlling the whole family's shopping and meal prep," she said. "If one person in a family is on a diet, the whole family is on a diet." This report by The Canadian Press was first published Sept. 13, 2026.

2h ago

Top Stories

Weight-loss drugs shaping up to be a boon for grocers' pharmacy units

While discount stores have been a bright spot recently for major grocery chains, other units within their empires have been quietly seeing a sales boom: their pharmacies. And it's largely coming from rising sales of weight-loss drugs. The popularity of Ozempic and other GLP-1 drugs, traditionally used to manage Type 2 diabetes, has exploded in recent years thanks to their weight-loss side effects. And as cheaper, generic versions become more widely available, uptake is only expected to rise further. Semaglutides, or GLP-1s as they're sometimes called, are the active ingredient in drugs like Ozempic. For grocers that have pharmacy units, signs of that growth are already noticeable in their financial reports. Loblaw Cos. Ltd., which owns Shoppers Drug Mart and Pharmaprix, reported a roughly 40 per cent surge in GLP-1 sales in each of its last two quarters. "We are beginning to see the impact of GLP-1 drugs going generic. It's still very early, but the initial indications are encouraging," Per Bank, chief executive of Loblaw, told analysts on an earnings call in July. Loblaw executives are projecting double-digit growth for GLP-1 sales in 2027. Metro Inc.'s outgoing chief executive, Eric La Flèche, struck a similar note during its earnings call last month. Metro owns Jean Coutu pharmacies. "Demand fundamentals remain strong with early evidence of increased patient adoption and higher prescription volumes," he said. Loblaw reported its drug retail same-store sales grew 4.6 per cent in its latest quarter, while Metro's pharmacy same-store sales were up 4.8 per cent. Both outpaced same-store sales metrics for food. The gains were driven by the prescriptions category. Even though generic versions of the drug mean lower prices, the growth in volume is still a net positive. "As generic supply continues to build, we expect ongoing expansion of the GLP-1 category to drive low-teens volume and contribution growth," La Flèche told analysts. That's "indicating that higher volumes should more than offset a meaningful portion of the price pressure from generalization," Veritas analyst Kathleen Wong said in a note about Metro's quarterly results in August. "The resulting price deflation is therefore likely to pressure pharmacy same-store sales measured in dollars, but Metro’s early experience suggests that increased accessibility and prescription volumes can offset part of that pressure at the contribution level." Health Canada has so far approved three generic semaglutide products, and is continuing to review more — making the country the first among G7 nations to do so. These used to be called the drug of the rich, said Amar Singh, senior director and head of Canadian retail insights at Kantar. "This drug was expensive, and now, with the generics coming out, this is increasing penetration as the cost has come down and more people can afford it," he said in an interview. Half of the respondents in a Leger poll from March said insurance coverage or a lower-cost generic would increase their likelihood of using a GLP-1. More than half cited weight loss as their primary reason for taking the drug. At that time, eight per cent — or three million Canadians — were on prescription GLP-1s, the survey suggested. With generics increasingly available in the market, Singh said he expects uptake to rise to about 20 per cent over the next year or two. That surge comes as Loblaw and Metro are expanding their pharmacy networks. Loblaw expects to have opened about 200 stores over the last three years, and roughly half are pharmacies, Wong said. Meanwhile, Empire acquired nine Morelli’s pharmacies in Ontario last month that are already situated within some Longo’s grocery stores. Jo-Ann McArthur, president of Nourish Food Marketing, said the increasing popularity of weight-loss drugs could be an opportunity for grocers to tailor customer experiences, especially as attitudes toward food change among weight-loss drug users. For instance, she said grocers could suggest GLP-1-friendly foods and offer meal planning through their loyalty apps, offer health-care insights for those on and off drugs, streamline store shelf labelling and market items that are weight-loss drug friendly. Late last year, Loblaw launched an online weight-management program for people to connect with health care practitioners and see if they qualify for the drugs. "Where they make more money (is) by providing more services and more advice and just making it easier for the consumer to just stay loyal," she said. And it's not just about keeping GLP-1 users within the same ecosystem. "People who are on these drugs often are controlling the whole family's shopping and meal prep," she said. "If one person in a family is on a diet, the whole family is on a diet." This report by The Canadian Press was first published Sept. 13, 2026.

2h ago

Most Watched Today